Summary: To determine the relationship between human papillomavirus (HPV) and endometrial carcinogenesis by comparing data from women with endometrial carcinoma to those of women with normal endometrial tissue. The survey was conducted for 100 women (50 with endometrial carcinoma and 50 with normal endometrial tissue) through HPV-DNA testing of paraffin-embedded endometrial tissue sections by polymerase chain reaction. Age, cigarette consumption, squamous differentiation and tumor grade, endometrium trophism, and HPV types detected in endometrial tissues were studied. HPV estimated odds ratio was similar in endometrial carcinoma and in normal endometrial tissue. The presence of HPV was not associated with age, tobacco abuse, endometrial histology status, squamous differentiation, or tumoral grade. DNA sequences of HPV types 16 and 18 were the most frequently detected in both groups. An association between HPV and endometrial carcinoma was not observed. Key Words: Human papillomavirus-Carcinogenesis-Endometrial carcinoma.
Endometrial carcinoma is one of the most common malignant gynecologic diseases in the western world. In many countries, it is considered the most frequent gynecologic cancer. With approximately 150,000 new cases diagnosed per year worldwide (1) , it is classically a disease of menopausal and older women. However, approximately 25% of cases are diagnosed before menopause, and 2% to 14% are found below 45 years of age. The risk factors for this neoplasia are yet to be determined in younger women (1) .
Systematic studies carried out in the 1980s showed different epidemiologic, clinical, pathologic, and molecular characteristics in women with endometrial carcinoma, associated with age, histologic type, and prognosis, which are currently divided into 2 different etiologies (2): (a) An estrogen-dependent factor, which most frequently occurs in younger women, associated with hyperestrogenism and an hyperplasic endometrium, and usually assumes the form of an endometrioid adenocarcinoma, rich in estrogenic and progesterone receptors, with a well-differentiated histologic grade. (b) A nonestrogen-dependent factor, which most frequently materializes in a serous adenocarcinoma, and is not associated with hyperestrogenism or hyperplasic endometrium. Whereas estrogen-dependent carcinomas are associated with mutations in the tumorsuppressor PTEN gene and of the Ras oncogenes and provide a better prognosis because of their relatively low morbidity, nonestrogen-dependent carcinomas are associated with a p53 mutation (3), and thus with a higher tumor cell proliferation. Both types of tumors might also be derived from other etiologic factors that are still not very well understood (2) .
Some authors have previously identified the presence of HPV in the uterine cavity (4-6) varying from 3% (7) to 64% (4, (8) (9) (10) (11) (12) (13) (14) (15) , whereas others have not found any presence of the virus (16) (17) (18) (19) (20) (21) . As research results are contradictory (7, 8, (16) (17) (18) (19) 22) , this study aimed to evaluate the possible relationship between HPV and endometrial cancer by observing paraffinconserved endometrial tissue blocks by using PCR analysis.
MATERIALS AND METHODS

Study Design
This case-controlled observational study analyzed samples of paraffin-embedded tissue from 50 cases of endometrial carcinoma and 50 cases with normal endometrium. Fifty women submitted to hysterectomy at the Gynecology and Obstetrics Service of the University Hospital of the Federal University of Santa Catarina, at the Hospital de Clı´nicas of the Federal University of Parana´and at a private clinic in Curitiba. Carriers of endometrial carcinoma comprised the case group, and 50 women, also submitted to hysterectomy, carriers of other (nonmalignant) pathologies with normal endometrium according to histopathology, comprised the control group. The histopathologic types of endometrial carcinomas were classified according to World Health Organization/International Society of Gynecological Pathology (WHO/ISGP) as endometrioid carcinoma (adenocarcinoma and adenocarcinoma with squamous metaplasia), mucinous adenocarcinoma, papillary serous adenocarcinoma, clear cell adenocarcinoma, adenosquamous carcinoma, undifferentiated carcinoma, and mixed carcinoma, and the histopathologic grades were grouped under well differentiated (G1), moderately differentiated (G2), and poorly or not differentiated (G3) (23) . The following types of endometrial carcinoma were found: endometrioid in 37 cases (74%), adenosquamous in 9 cases (18%), and others (papillary serous adenocarcinoma, clear cell adenocarcinoma, undifferentiated carcinoma, and mixed carcinoma) in 4 cases (8%).
The control group was comprised of women submitted to surgery (hysterectomy) for benign pathologies such as leyomiomas, uterine prolapse, and adenomiosis. In this group, the endometrial tissue was classified as trophic (31 cases) or atrophic (19 cases) . No cases of squamous or morular metaplasia were observed in normal endometrial tissue.
Exclusion Criteria
Women with endometrial carcinoma in which the location of the primary lesion was unclear, for example, an initial carcinoma of the uterine cervix, of the bladder or of the rectum with subsequent endometrial invasion, were excluded from the case group, as were women with an earlier or current history of preneoplastic lesions (cervical intraepithelial neoplasia, vulvar intraepithelial neoplasia, or other), and of carcinoma of the low genital tract, treated or not treated. All women with endometrial or lower genital tract preneoplastic lesions, and women earlier submitted to any antineoplasic treatment (radiotherapy or chemotherapy) were excluded from the control group.
Detection of HPV-DNA
The 100 most representative samples of paraffinembedded tissue were selected and reexamined by the same pathologist (Irene Vieira de Souza), and an investigation on the histologic type, the differentiation grade, and on the areas of squamous differentiation was performed according to WHO/ISGP (23) .
A section from each paraffin-embedded block was cut at 6 mm, and the DNA was extracted according to Banerjee et al's method (24), with modifications. DNA samples were submitted to polymerase chain reaction (PCR) with b-globinprimers PCO3/PC04, which amplify a DNA fragment of 110 bp and served as an internal control to evaluate the integrity and sufficiency of the DNA extracted from specimens (25) . The reaction was standardized by the following sequence of oligonucleotides: PCO3: 5 0 -ACA-CAACTGTGTGTTCACTAGC-3 0 and G74: 3 0 -CAACTTCATCCACGTTCAC-5 0 . For detection of HPV-DNA, general primers GP5 þ /GP6 þ were used to amplify a fragment of approximately 150 bp. PCR products were typed with dot-blot hybridization using probes 6, 11, 16, 18, 31, 33, 34, 35, 39, 40, 42, 43, 44, 45, 51, 54, 52, 54, 56, and 58 labeled with P32 isolated or in cocktail (26) . In all reactions and hybridizations, positive and negative
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controls were added, including DNA from HPVpositive cervical cell lines (HeLa and SiHa, HPV 18 and 16 positive, respectively), from C33, and an HPV-negative cervical cancer cell line, and reactions were observed without any added DNA as reactionnegative controls. The estimated analytical sensitivity of this method is 0.5 to 1 copy of HPV-DNA per total DNA added to the reaction.
Statistical Analysis
Calculation of odds ratio (OR) for the presence of HPV-DNA in the samples and the Fischer exact test were performed with a 95% confidence interval (CI). A level of Po0.05 was accepted as statistically significant.
For the statistical analysis of the 2 populations, the Fischer exact test was used instead of w 2 test due to the small sample size. Compared results often showed a value less than 5.
RESULTS
HPV-DNA was detected in 4 cases of endometrial carcinoma (8%) and in 5 cases of normal endometrial tissue (10%). The OR for the presence of HPV-DNA in the endometrial tissue samples was the same in the carriers of endometrial carcinoma, compared with the histologic samples of women without cancer (OR ¼ 0.78, 95% CI ¼ 0.16-3.66) ( Table 1) .
There was no statistically significant difference in the presence of HPV-DNA in the endometrial tissue of the women with or without endometrial carcinoma, aged less than or equal to 50 years (8% and 5%, respectively), (OR ¼ 1.58, 95% CI ¼ 0.6-5.41) and 8% and 13%, respectively, among the women over 50 years of age (OR ¼ 0.57, 95% CI ¼ 0.09-3.42) ( Table 1) .
The presence of HPV-DNA in endometrial tissue of women with or without endometrial carcinoma did not seem to be statistically significantly different when age and smoking habits were considered (Table 1 ). In the group of women with endometrial carcinoma, we observed that the presence of HPV-DNA was very similar in smokers (7%) and nonsmokers (9%). In the group of women without carcinoma, although HPV-DNA was 3.5 times more frequent among the smokers than among the nonsmokers (7% vs. 25%), this difference was not statistically significant.
The frequency of HPV-DNA in the endometrial tissue samples of the patients with endometrial carcinoma was similar in the presence or absence of squamous differentiation (11% and 10%, respectively).
The evaluation of the histopathologic grades did not enable us to observe any difference with regard to HPV presence. We observed the presence of HPV-DNA in 7% of the well-differentiated degree cases and in 12% of the moderately or poorly differentiated degree cases (P ¼ 0.513).
No statistical difference could be observed when comparing the endometrial histologic status (trophic or atrophic) among the patients without endometrial carcinoma with HPV-DNA identified, even if double the number of cases presented a trophic endometrial histologic status compared with those with an a trophic status (12% vs. 6%; P ¼ 0.440). In this study, HPV 16 was the most frequently detected type (10%). HPV 18 was found exclusively in women with normal endometrium (6%), whereas its association with HPV 31 was detected in 1 case of endometrial carcinoma (Table 2) .
DISCUSSION
All the research on endometrial carcinoma to date reports that its oncogenesis is directly related to the prevalence of an estrogenic hormone action. This factor does not, however, explain all of the cases, especially those occurring in younger patients, in whom this hormonal risk factor should not be present. HPV-DNA identification in the upper genital tract (in benign and malignant alterations) is not uncommon, and its implications are still unknown (4) (5) (6) 12, 15) . If endometrial carcinoma oncogenesis has not yet been fully explained, even by isolated new theories on the alterations of PTEN, Ras, and p53 genes (3), could these alterations of the tumor suppressor genes not be associated with other factors that might have been ignored, such as HPV, for example? Despite the increase in the incidence of endometrial adenocarcinoma in recent years, this disease remains uncommon in women in the premenopausal period (2), and mostly strikes women over 50 years.
This study did not highlight any difference in HPV-DNA-positive rate between age groups (r50 y of age and 450 y). The fact that our control group had almost twice as many women in the lower age group (42% vs. 24%) does not affect the accuracy of the statistical measurements, but reflects a flaw in the study design. HPV-DNA prevalence was 8% in both groups, whereas in the upper age group, HPV presence was 2.5 times higher in women without carcinoma (P ¼ NS).
The 8% rate of endometrial carcinoma with HPV-DNA found in this study is close to the rates recorded by Fujita et al. (6, 9) , who reported a rate of 7% in 1 small sample study (9) and 9% in another (6) , and to the rate recorded by Ip et al. (12) , who found a 9.1% occurrence of high-risk HPV-DNA in women from Hong Kong with endometrial carcinoma. If, on the one hand, other investigations demonstrated much higher positive rates, varying from 22 to 64% (4, 8, 10, 11, (13) (14) (15) , on the other, the great majority of the studies did not compare the presence of HPV in normal endometrial tissue and endometrial carcinomas (5) (6) (7) (8) (9) (10) (12) (13) (14) (15) (16) (17) (18) (19) (20) 27) . These conflicting results may be associated with the dissimilarities among the analyzed populations or between the methodologies used, especially between those used to detect HPV-DNA, showing either false-positive or negative results.
Endometrial adenocarcinomas may show areas with benign squamous differentiation (adenoacanthomas) or malignant squamous differentiation (adenosquamous carcinomas). The origin of the latter is still largely ignored, but O'Leary et al. (11) and Zidi et al. (17) believe that HPV may be involved in its genesis. The authors found a possible association of low risk HPV (6 and 11) and squamous metaplasia of endometrium. O'Leary et al. found HPV 6 in 22% of the cases of adenocarcinomas with benign squamous differentiation, suggesting a possible interaction of HPV in the pathogenesis of squamous metaplasia at extracervical sites. In our study, we evaluated this possibility but did not find any difference, as HPV was present in 11% of the cases with squamous differentiation and in 10% without this differentiation. The possibility that HPV may simply be present in areas of squamous differentiation should be considered. All HPV types isolated were of high oncogenic risk (HPV-DNA types 16, 18, and 31). Some areas of squamous differentiation may not have been identified as well due to the difficulty in evaluating the tumor in all its extension, as, generally, only some of the tissue cuts are studied. Other authors (17, 18, 21) did not detect HPV in endometrial squamous cell carcinomas, whereas Kataoka et al. (22) found HPV-DNA type 31 in 1 case, and Horn et al. (27) consumption and endometrial cancer. Although smoking is usually considered a strong factor in the development and evolution of precancerous lesions of the lower genital tract, when associated with HPV infection, several studies suggest that tabagism may have a protecting effect against the development of endometrial cancer (1). We thus tried to find out whether the presence of HPV-DNA in the endometrial tissue was somewhat related to the patient's habit of smoking.
When only the smokers were evaluated, we found the OR of the presence of HPV in endometrial tissue with cancer to be 5 times lower than that in normal endometrium, although this difference was not statistically significant. The apparent difficulty for HPV to settle in a neoplasic endometrium among the smokers disappeared when we compared the presence of the virus in women who smoked to nonsmokers with endometrial cancer (7% and 9%, respectively). It is interesting, nonetheless, that we found 3.5 times more presence of HPV-DNA in the normal endometrium of the smokers, even though this difference was not statistically significant.
Several methodologic limitations hinder the evaluation of a larger number of cases, such as the low incidence of the disease and the difficulty in selecting women with similar characteristics.
Apart from the fact that most studies were carried out among a small number of women, and often compared cervical and endometrial adenocarcinoma samples, several factors may have interfered in the different rates of HPV prevalence found in earlier studies, and their actual methodology, for example, the choice of the detection method, and different nonappraised risk factors (low socioeconomic level, number of sexual partners, interaction with other sexually transmitted infections, smoking habits).
HPV-DNA might also not have been detected in a number of studies due to the low sensitivity of the techniques used. Even in PCR, which is considered the most sensitive technique for HPV-DNA detection, false-positive results may sometimes appear, as contamination is not rare. A summary of the percentages of HPV, detected by PCR, in women with normal endometrium and with carcinoma in earlier studies can be seen in Table 3 .
We had expected to find a larger number of positive cases of HPV in women with endometrial carcinoma, but heterogeneity among the groups as regard age, weight, hormonal alterations, and histologic types may have impacted the results. Our findings did not confirm the hypothesis of HPV involvement in the genesis of any of the endometrial carcinomas detected.
